ITP; chest pain; This spontaneous case was reported by a patient and describes the occurrence of IMMUNE THROMBOCYTOPENIA (ITP) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In 2022, the patient experienced IMMUNE THROMBOCYTOPENIA (ITP) (seriousness criterion medically significant) and CHEST PAIN (chest pain). At the time of the report, IMMUNE THROMBOCYTOPENIA (ITP) and CHEST PAIN (chest pain) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2022, Platelet count: 195. On 08-Aug-2022, Platelet count: dropped to 14.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  It was reported that 3-4 months ago he had a physical where his platelet levels were at 195.  2-3 weeks ago he went to the hospital with chest pain where he had blood drawn. He was given steroids and was on his 3rd course currently. Yesterday his platelets had dropped to 14, and he had an infusion today. He was scheduled to take another infusion tomorrow. With these platelet levels he was recently diagnosed with "ITP." He has discussed his symptoms with his PCP and hematologist. "Patient doctors think that this may be related to something with the Moderna vaccine." He has had no prior diagnosis of myocarditis or pericarditis.  The treatment includes steroids Infusions(unspecified).  Company Comment:  This spontaneous case concerns an elderly male patient with no reported medical history, who experienced the unexpected, serious  (medically significant) adverse event of special interest Immune thrombocytopenia (ITP) that occurred on an unspecified date after receiving the fourth dose of mRNA-1273 vaccine.  Patient had a previous platelet count reported as 195 a few months prior to vaccination. Sometime in the following month of vaccine administration, patient presented with chest pain and had an unspecified blood test with undisclosed result. Steroid therapy was then started, and patient was reportedly on his 3rd course. Approximately 3 weeks later, his platelets dropped to 14, and was diagnosed with Immune thrombocytopenia for which infusion therapy was given.  Patient previously received 3 mRNA-1273 vaccines consisting of a 2-dose primary series given 28 days apart, followed by a third dose administered approximately 7 months prior to current vaccine.   The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2022-626342 (Patient Link).; Sender's Comments: This spontaneous case concerns an elderly male patient with no reported medical history, who experienced the unexpected, serious  (medically significant) adverse event of special interest Immune thrombocytopenia (ITP) that occurred on an unspecified date after receiving the fourth dose of mRNA-1273 vaccine.  Patient had a previous platelet count reported as 195 a few months prior to vaccination. Sometime in the following month of vaccine administration, patient presented with chest pain and had an unspecified blood test with undisclosed result. Steroid therapy was then started, and patient was reportedly on his 3rd course. Approximately 3 weeks later, his platelets dropped to 14, and was diagnosed with Immune thrombocytopenia for which infusion therapy was given.  Patient previously received 3 mRNA-1273 vaccines consisting of a 2-dose primary series given 28 days apart, followed by a third dose administered approximately 7 months prior to current vaccine.   The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.